Gene-Eden-VIR is a natural treatment desinged to help the immune system target the latent Epstein Barr Virus (EBV).
A post marketing clinical study showed that Gene-Eden-VIR decreased symptoms of an EBV infection. The study followed
the FDA guidelines for clinical studies.
The following information was published by the Centers for Disease
Control and Prevention (CDC) on its website. In brackets and italic
letters, you can find our comments on the CDC information. Also note
our yellow highlights.
Kill the virus!
We accept all types of credit cards (credit, debit, pre-paid, etc.). Sorry, we don't accept other modes of payment.
To keep your privacy, your bank or credit card statements will show the name of our parent company. For obvious reasons we don't mention it here.
For your security, we will never call you and ask for your credit card number, or personal information over the phone.
Gene-Eden-VIR is only available on this website. Gene-Eden-VIR is not sold in stores, or on other websites.
Epstein-Barr virus, frequently referred to as EBV, is a member of the
herpesvirus family and one of the most common human viruses. The virus
occurs worldwide, and most people become infected with EBV sometime
during their lives. In the United States, as many as 95% of adults
between 35 and 40 years of age have been infected. Infants become
susceptible to EBV as soon as maternal antibody protection (present at
birth) disappears. Many children become infected with EBV, and these
infections usually cause no symptoms or are indistinguishable from the
other mild, brief illnesses of childhood. In the United States and in
other developed countries, many persons are not infected with EBV in
their childhood years. When infection with
EBV occurs during adolescence
or young adulthood, it causes infectious mononucleosis 35% to 50% of the
Symptoms of infectious mononucleosis are fever, sore throat, and swollen
lymph glands. Sometimes, a swollen spleen or liver involvement may
develop. Heart problems or involvement of the central nervous system
occurs only rarely, and infectious mononucleosis is almost never fatal.
There are no known associations between active EBV infection and
problems during pregnancy, such as miscarriages or birth defects.
Although the symptoms of infectious mononucleosis usually resolve in 1
or 2 months, EBV remains in a latent state in a few cells in the throat
and blood for the rest of the person's life. Periodically, the virus can
reactivate and is commonly found in the saliva of infected persons. This
reactivation usually occurs without symptoms of illness.
EBV also establishes a lifelong latent infection in some cells of the
body's immune system. A late event in a very few carriers of this virus
is the emergence of Burkitt's lymphoma and nasopharyngeal carcinoma, two
rare cancers that are not normally found in the United States. EBV
appears to play an important role in these malignancies, but is probably
not the sole cause of disease.
Most individuals exposed to people with infectious mononucleosis have
previously been infected with EBV and are not at risk for infectious
mononucleosis. In addition, transmission of EBV requires intimate
contact with the saliva (found in the mouth) of an infected person.
Transmission of this virus through the air or blood does not normally
occur. The incubation period, or the time from infection to appearance
of symptoms, ranges from 4 to 6 weeks.
Persons with infectious
mononucleosis may be able to spread the infection to others for a period
of weeks. However, no special precautions or isolation procedures are
recommended, since the virus is also found frequently in the saliva of
healthy people. In fact, many healthy people can carry and spread the
virus intermittently for life. These people are usually the primary
reservoir for person-to-person transmission. For this reason,
transmission of the virus is almost impossible to prevent.
The clinical diagnosis of infectious mononucleosis is suggested on the
basis of the symptoms of fever, sore throat, swollen lymph glands, and
the age of the patient. Usually, laboratory tests are needed for
confirmation. Serologic results for persons with infectious
mononucleosis include an elevated white blood cell count, an increased
percentage of certain atypical white blood cells, and a positive
reaction to a "mono spot" test.
There is no specific treatment for infectious mononucleosis, other than
treating the symptoms. No antiviral drugs or vaccines are available.
[Gene-Eden-VIR was designed to help the immune system target latent viruses, including the EBV.
A clinical study published in the important medical journal Pharmacology and Pharmacy showed that Gene-Eden-VIR
decreased the symptoms reported by people suffering from an EBV infection.]
Some physicians have prescribed a 5-day course of steroids to control
the swelling of the throat and tonsils. The use of steroids has also
been reported to decrease the overall length and severity of illness,
but these reports have not been published.
It is important to note that symptoms related to infectious
mononucleosis caused by EBV infection seldom last for more than
months. When such an illness lasts more than
6 months, it is frequently
called chronic EBV infection. However, valid laboratory evidence for
continued active EBV infection is seldom found in these patients. The
illness should be investigated further to determine if it meets the
criteria for chronic fatigue syndrome, or CFS. This process includes
ruling out other causes of chronic illness or fatigue.